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Introduction: Predictors of financial costs related to total joint
arthroplasty (TJA) have become increasingly important becuase
payment methods have shifted from fee for service to bundled
payments. The purpose of this study was to assess the relationship
between preoperative opioid use and cost of care in primary TJA.
Methods: A retrospective study was conducted in Medicare patients
who underwent elective unilateral primary total knee or hip
arthroplasty between 2015 and 2018. Preoperative opioid usage,
comorbidities, length of stay, and demographic information were
obtained from chart review. The total episode-of-care (EOC) cost data
was obtained from the Centers of Medicare and Medicaid Services
based on Bundled Payments for Care Improvement Initiative Model 2,
including index hospital and 90-day postacute care costs. Patients
were grouped based on preoperative opioid usage. Costs were
compared between groups, and multivariate linear regression
analyses were performed to analyze whether preoperative opioid
usage influenced the cost of TJA care. Analyses were risk-adjusted for
patient risk factors, including comorbidities and demographics.
Results: A total of 3,211 patients were included in the study. Of the
3,211 TJAs, 569 of 3,211 patients (17.7%) used preoperative opioids, of
which 242 (42.5%) only used tramadol. EOC costs were significantly
higher for opioid and tramadol users than nonopioid users ($19,229
versus $19,403 versus $17,572, P , 0.001). Multivariate regression
predicted that the use of preoperative opioids in TJA was associated
with increased EOC costs by $789 for opioid users (95% confidence
interval [CI] $559 to $1,019, P , 0.001) and $430 for tramadol users
(95% CI $167 to $694, P = 0.001). Total postacute care costs were
also increased by 70% for opioid users (95% CI 44% to 102%, P ,
0.001) and 48% for tramadol users (95% CI 22% to 80%, P , 0.001).
Discussion: This study demonstrated that preoperative opioid usage
was associated with higher cost of care in TJA. Limiting preoperative
opioid use for pain management before TJA could contribute to cost
savings within a bundled model.

M

ost clinical practice guidelines
recommend treating hip and
knee osteoarthritis pain with an
analgesic pathway, starting with acetaminophen or NSAIDs, followed by

intra-articular corticosteroid injections,
and finally, total joint arthroplasty
(TJA). Despite efforts to address the
opioid epidemic, the literature demonstrates that physicians are still
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prescribing opioids to treat chronic
osteoarthritis pain, with recent studies reporting that 17 to 39.4% of patients undergoing TJA were prescribed
opioids before surgery.1-6
Within the orthopaedic surgery literature, preoperative opioid use led to
higher complications, longer hospital
length of stay (LOS), higher rates of
discharge to extended care facilities,
higher rates of 30-day readmissions,
increased number of revision TJA, and
increased morbidity and mortality, all
of which can affect the cost and
reimbursement within the bundled
care payment system.1,7-11 Although
previous studies within spinal and
abdominal surgery patients reported
higher total costs associated with
preoperative opioid usage,12-14 to our
knowledge, no similar studies exist
within the TJA literature.
Predictors of financial cost have
become increasingly important in the
wake of the Centers for Medicare and
Medicaid Services (CMS) using alternative payment models such as the
Bundled Payment for Care Improvement Initiative. Because TJAs are
among the most common surgical
procedures performed in the United
States,15 costs have important economic implications for providers,
institutions, and insurers. Thus, determining the role of preoperative
opioid use on the total financial expenses of TJA could shed light on
potential costs and identify costsaving measures. Therefore, the primary purpose of this study was to
assess the relationship between preoperative opioid use and 90-day
episode-of-care (EOC) cost for primary TJA. Second, we determined
if preoperative opioid use had an
impact on short-term outcomes
measures that influenced cost, such as
discharge disposition or 90-day readmissions. Finally, we sought to
determine the independent effect of
preoperative opioid use on costs
when controlling for confounding
factors.

2

METHODS
Study Design and Patient
Cohort
A retrospective, observational study
within a single institution was conducted on Medicare patients who
underwent elective unilateral primary
total knee arthroplasty and total hip
arthroplasty (THA) between January
1, 2015, and September 30, 2018. A
total of 3,211 patients were eligible for
inclusion in the study, and none of
these patients were from subacute
nursing facilities. Institutional Review
Board approval was obtained before
conducting this study. Patient medications were manually documented
from preadmission testing notes. Preoperative opioid users were defined as
patients who had one or more opioid
medications reported as current medication in the last outpatient note before
surgery or in preadmission testing
notes. The duration of opioid use
could not be determined from these
notes. Opioid medications included
tramadol, oxycodone, hydrocodone,
codeine, hydromorphone, and other
opioid medications (Table 1). Patients
were divided into one of three groups
according to preoperative opioid use;
1—No Opioids, 2—Tramadol Only,
and 3—All Opioids, which did not
include tramadol only users. Demographic information including age,
sex, race, body mass index, Charlson
Comorbidity index, and joint type
(knee or hip) along with the hospital
LOS were recorded from electronic
medical records.
Cost of care data were based on
financial information obtained from
CMS Bundled Payments for Care
Improvement Model 2 claims data.
Model 2 is a retrospective bundled
payment model where fee-for-service
payments for TJA are reconciled
against target prices. This model incentivizes providers who are able to
effectively reduce the cost of care
without compromising the quality.

Cost data from this model include
reimbursements from time of admission to 90-days postdischarge. Total
EOC costs included all inpatient
and outpatient costs. Total index
costs included any inpatient charges,
whereas total postacute care (PAC)
costs included any payments postdischarge, which included, but were
not limited to, discharge facilities,
home health aides, and physical
therapy.

Statistical Analysis
Demographics, costs, and outcomes
were compared between groups. Continuous variables were reported as
mean and standard deviation and
compared using Kruskal-Wallis tests
because they were all nonparametric in
distribution. Categorical variables were
reported as counts and percentages
and compared using chi-square analysis. Multivariate regression models
were conducted to evaluate the relative
impact of preoperative opioids usage
on EOC cost, total index cost, and total
PAC costs. Because financial data are
not normally distributed, data transformations were required to obtain
normality for each group. For EOC
cost, costs in the upper and lower 15th
percentiles were winsorized, respective
to the mean raw cost. Total index costs
in the upper and lower 10th percentiles
were also winsorized. Total PAC cost
and LOS were normalized with log
transformations. P-values less than
0.05 were considered statistically significant. Statistical analysis was performed using R version 3.6.3 (R
Foundation for Statistical Computing).

RESULTS
Of the 3,211 patients included in the
study, there were 1,663 total knee
arthroplasties and 1,548 THAs, and
1,282 (39.9%) were men. The overall
prevalence of preoperative opioid
usage was 17.7% (569 of 3,211), of
which 242 patients (42.5%) only
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used tramadol. Of the opioids consumed, tramadol (48.3%, 275 of
569) and oxycodone (30.4%, 173 of
569) were the most commonly used
(Table 1). Some patients had more
than one opioid prescribed. Significant differences between the groups
were observed for age, sex, Charlson
Comorbidity index, and ethnicity
(Table 2).
Total EOC costs were significantly
higher for the All Opioids and Tramadol Only groups compared with
the No Opioids group ($19,229 versus $19,403 versus $17,572, P ,
0.001, Table 3). This difference was
because of both a difference in total
index costs ($13,868 versus $13,778
versus $13,679, P , 0.001) and PAC
costs ($5,361 versus $5,625 versus
$3,893, P , 0.001).
When comparing outcomes, mean
LOS was greater for the All Opioids
and Tramadol Only groups compared with the No Opioids group
(2.0 days versus 1.9 days versus
1.6 days, P , 0.001) (Table 3). In
addition, patients using opioids or
tramadol were twice as likely to be
discharged to a facility (14% versus 14% versus 7%, P , 0.001),
specifically skilled nursing facilities
(18% versus 14% versus 7%, P ,
0.001). No significant difference was
observed, however, for complication
rates (4% versus 3% versus 3%, P =
0.555) or readmission rates (7%
versus 5% versus 5%, P = 0.302)
between groups.
In a multivariate analysis, controlling for confounding factors, total
EOC costs were $789 greater for
opioid users (95% confidence interval [CI] $559 to $1019, P , 0.001)
and $430 (95% CI $167 to $694,
P = 0.001) for tramadol users (Table
4) compared with nonopioid users.
Opioid use and tramadol use also
increased total index costs by $74
(95% CI $45 to $102, P , 0.001)
and $39 (95% CI $6 to $72, P =
0.020), respectively (Table 5). A
more profound effect was observed

for PAC costs, where opioid use
was associated with a 70% increase
(95% CI 44% to 102%, P , 0.001)
and tramadol use was associated
with a 48% increase (95% CI 22%
to 80%, P , 0.001, Table 6) compared with nonopioids users.

DISCUSSION
Using Medicare reimbursement
payments, this study evaluated the
impact of preoperative opioid use on
the cost of TJA. Preoperative opioids,
even tramadol alone, were found to
markedly account for increased total
episode, index, and postacute costs of
primary knee and hip arthroplasty
surgeries. In addition to cost, our
study also demonstrated that preoperative opioids use was associated
increased health utilization, specifically increased LOS and likelihood of
discharge to a skilled care facility.
Research has shown an increasing
prevalence of preoperative opioid utilization in elective orthopaedic patients,
which is associated with increased
mortality and morbidity in the postoperative period.16 In the postsurgical
period, opioid users are known to have
increased opioid-related adverse events
such as ileus, respiratory failure, and
requirement of mechanical ventilation.8,16 Previous opioid users have
lower pain thresholds, opioid-induced
hyperalgesia, and associated increased
in postoperative opioid use.7,17 In
addition, previous opioid use in TJA
patients is associated with increased
periprosthetic joint and surgical site
infection rates.16,18 Opioid users have
also been found to have increased
hospital utilization including increased
length of inpatient stay, increased use
of physiotherapy, and nonroutine discharge.1,12,13,19 Based on the above,
one may infer that TJA patients with
preoperative opioid use may increase
the overall cost of care; however, cost
utility analyses of preoperative opioid
use in TJA are scarce in the literature.

Table 1
Opioid Usage
Opioid Used
Tramadol
Oxycodone
Hydrocodone
Codeine
Fentanyl patch
Hydromorphone
Buprenorphine
patch
Tapentadol
Morphine
Methadone

No. of
Patients
275
173
87
47
10
8
5
3
2
1

Previous studies have investigated the
cost in patient cohorts with degenerative lumbar stenosis and those undergoing abdominal surgery.12-14
A study by Tye et al12 based on the
Ohio Bureau of Workers’ Compensation data found that patients with
degenerative lumbar stenosis who
were prescribed opioids for greater
than 3 months before surgery
incurred over $70,000 more in total
medical costs compared with those
who received opioids for less than
3 months before surgery. In the same
study, long-term opioid user group
also had higher opioid use postoperatively and also had more psychiatric
diagnoses postsurgery. The cost difference between the groups was substantially higher than in our study,
likely because of several key differences in study cohort and design. Our
study cohort was exclusively comprised Medicare patients.20 In addition, we were unable to determine
opioid prescription strength or length
of opioid use before TJA in this study,
which precluded our ability to distinguish short-term from long-term
opioid users in our analysis. In addition, Tye et al evaluated the total costs
incurred over the 3-year postoperative
period, whereas our study only evaluated 90-day costs.
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Table 2
Patient Characteristics
Demographic Variable
Age
Sex
Females
Men
Body mass index (kg/m2)
Charlson Comorbidity index
Ethnicity
Caucasian
African American
Other
Joint
Hip
Knee

No Opioids
N = 2,642

All Opioids
N = 327

Tramadol Only
N = 242

71.7 (6.41)

69.8 (8.34)

71.9 (7.86)

1,557 (58.9%)
1,085 (41.1%)
29.3 (4.99)
2.22 (1.89)

204 (62.4%)
123 (37.6%)
30.0 (5.50)
1.46 (1.69)

168 (69.4%)
74 (30.6%)
29.5 (5.26)
1.75 (1.83)

2,132 (85.6%)
228 (9.15%)
131 (5.26%)

247 (78.4%)
58 (18.4%)
10 (3.17%)

187 (81.3%)
32 (13.9%)
11 (4.78%)

1,247 (47.2%)
1,395 (52.8%)

169 (51.7%)
158 (48.3%)

132 (54.5%)
110 (45.5%)

P Value
,0.001a,b
0.004a

0.066
,0.001a,c
,0.001c

0.038

a

No opioids significantly differed from tramadol only.
All opioids significantly differed from tramadol only.
No opioids significantly differed from all opioids.
Reported as mean (SD) or n (%), bold denotes statistical significance.

b
c

Although preoperative opioid use
did not have as large an impact on
cost in our study, demonstrating differences in the hundreds of dollars for
categories such as total index cost or
postacute skilled facility costs, TJA
has become one of the most common
surgical procedures. A 2018 review
of the National Inpatient Sample data
estimates the rates of TJA to increase
by greater than 70%, reaching over
1.5 million cases performed annually
by 2030.21 Considering the incidence
of opioid use and cost differences
observed in our study, we estimate
that preoperative opioid use would
incur greater than $177 million in
TJA EOC expenses for CMS by
2030. This would represent a notable source of potential savings for
CMS if rates of preoperative opioid
use can be decreased, even with the
reduction of tramadol alone.
A similar study conducted by
O’Donnell et al13 reported that opioid use defined for more than 90 days
before lumbar diskectomy was
an independent predictor of higher

4

medical costs because the opioid user
group had higher resource utilization
for postoperative care. Waljee et al14
reported that preoperative opioid use
was associated with markedly greater
cost expenditures at 90, 180, and
365 days after elective abdominal
surgery. Although their study found
no notable differences in inpatient
costs, this differed from our results
where inpatient costs were increased
in reported opioid user group most
likely secondary to increased LOS.
In the current study, preoperative
opioid users were more likely to have
longer length of inpatient stay and more
likely be discharged to nonhome locations compared with nonopioid users.
A study by Pivec et al19 found significantly increased LOS in patients with
previous opioid use undergoing THA.
In their study, opioid users stayed 4
hospital days compared with 3 days
for the nonopioid group. In another
study by Zarling et al,11 the authors
reported a trend toward increased
nonhome discharge in opioid patients
who underwent TJA. In their study,

31% of patients who used chronic
preoperative opioids ($2 opiate prescriptions filled for 6 weeks in the
3 months before surgery) were discharged to extended care facilities
compared with 21% of the control
group. Using the national inpatient
sample data, Menendez et al16 found
that opioid users undergoing elective
orthopaedic procedures had markedly
more nonhome-bound discharge and
increase in length of inpatient stay. We
hypothesize that these preoperative
opioid users have lower pain threshold, increased use of opioids in the
postoperative period because of opioid-induced hyperalgesia, decreased
mobilization, and increased utilization
of postoperative care including physical therapy as possible causes for this
finding.
Our findings were similar to those
found by Chen et al,22 who demonstrated that patients with documented
opioid dependence had significantly
higher total hospital charges. Our
findings were unique from theirs in that
we considered any patient using opioid
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Table 3
Comparison of Costs and Outcomes
No Opioids
N = 2,642

Variable
Short-term outcome measures
LOS (d)
Discharge to facility
Skilled nursing facility
Inpatient rehab
Long-term acute care
90-d complications
90-d readmission
EOC costs
Total episode cost
Total index cost
Index facility cost
Index part B services
Index DME
Total PAC cost
IRF cost
SNF cost
HHA cost
Outpatient cost
Part B cost
DME cost
Readmission cost

All Opioids
N = 327

1.59 (1.05)
193 (7.31%)
81 (6.67%)
17 (1.40%)
1 (0.08%)
78 (3.04%)
141 (5.34%)
17,572 (7,731)
13,679 (754)
11,615 (665)
1,266 (792)
7.62 (28.3)
3,893 (7,656)
197 (2,008)
778 (3,422)
473 (1,253)
554 (1,160)
1,609 (1,898)
35.7 (139)
557 (3,268)

2.02 (1.42)
44 (13.5%)
39 (17.8%)
4 (1.83%)
1 (0.46%)
13 (4.15%)
24 (7.34%)
19,229 (8,772)
13,868 (1,077)
11,764 (993)
1602 (762)
11.1 (31.9)
5,361 (8,621)
356 (2,672)
1,406 (3,989)
817 (1,470)
610 (991)
1,618 (1,876)
57.9 (179)
616 (3,171)

Tramadol Only
N = 242

P Value

1.86 (1.18)
33 (13.6%)
26 (13.9%)
5 (2.67%)
0 (0.00%)
8 (3.42%)
12 (4.96%)

,0.001a,b
,0.001a,b
,0.001a,b
0.335
0.439
0.555
0.302

19,403 (11,310)
13,778 (1,149)
11,696 (929)
1,742 (879)
6.26 (20.1)
5,625 (11,068)
622 (3,483)
1,674 (5,320)
727 (1,437)
449 (723)
1,540 (1,770)
47.1 (160)
679 (4,290)

,0.001a,b
,0.001a
,0.001a
,0.001a,b
0.296
,0.001a,b
0.015b
,0.001b
,0.001a,b
0.049
0.722
0.318
0.339

DME = durable medical equipment, EOC = episode of care, HHA = home health aide, IRF = inpatient rehabilitation facility, LOS = length of stay, PAC
= postacute care, SNF = skilled nursing facility
a
No opioids significantly differed from all opioids.
b
No opioids significantly differed from tramadol only.
Reported as mean (SD) or n (%), bold denotes statistical significance.

Table 4
Total Episode Cost Predictive Factors
Variable
Age
Body mass index
Male sex
Joint (knee versus hip)
All opioids with no tramadol
Tramadol only

Estimate ($)

95% CI Lower Bound

95% CI Upper Bound

P Value

47.16
11.86
2301.08
1,001.86
789.16
430.40

36.75
22.20
2442.60
861.41
559.13
166.98

57.56
25.93
2159.57
1,142.32
1,019.19
693.82

,0.001
0.098
,0.001
,0.001
,0.001
0.001

CI = confidence interval
Bold denotes statistical significance.

medications preoperatively to be an
opioid user and were able to demonstrate that preoperative opioid use

had a large effect on PAC costs. Similar
to their study, we observed notable
differences in patient demographics

and comorbidities between groups.
These findings agreed with other literature showing that opioid prescribing
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Table 5
Total Index Cost Predictive Factors
Variable
Age
Body mass
index
Male sex
Joint (knee
versus hip)
All opioids with
no tramadol
Tramadol only

Estimate
($)

95% CI Lower
Bound

95% CI Upper
Bound

P
Value

0.92
2.13

20.37
0.39

2.21
3.88

0.163
0.017

24.60
42.66

222.15
25.24

12.96
60.08

0.608
,0.001

73.90

45.36

102.44

,0.001

38.85

6.18

71.53

0.020

CI = confidence interval
Bold denotes statistical significance.

these limitations, we were able to
demonstrate that preoperative opioid
use is significantly associated with
increased EOC costs.
In conclusion, preoperative opioid
use, whether full or partial opioid agonists, is associated with higher total
episode costs, higher total index costs,
higher PAC costs, longer LOS, and
increased nonhome discharge in primary, elective TJA patients. In the era of
bundled payments, limiting or eliminating opioids for preoperative pain
management before joint replacement
could be one avenue to reduce the
overall cost of care.

References
Table 6
Total Postacute Care Cost Predictive Factors
Variable
Age
Body mass
index
Male sex
Joint (knee
versus hip)
All opioids with
no tramadol
Tramadol only

Estimate
(%)
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Bound

P
Value
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demonstrate a significant relationship
between preoperative opioid use and
EOC costs.
This study had several limitations
that should be considered. First, the
study was dependent on the willingness of the patient to truthfully divulge
their medications and the accuracy of
documentation because preoperative
opioid usage was manually recorded

6

from the last outpatient note before
surgery or preadmission testing notes.
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was reported as binary all or none
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true dosage, duration, and frequency
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Third, we did not record functional
outcomes. Fourth, our study cohort
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variation among patients; however,
costs are multifactorial and depends
on a wide variety of factors. Despite
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